A study presented at the European Academy of Dermatology and Venereology meeting linked GLP-1 receptor agonists to nail disorders, particularly onycholysis (separation of the nail from the nail bed) and dyschromia (discoloration). Among 575 GLP-1 users, 39.3% had onycholysis versus 8.7% of 1,329 obese or diabetic controls who never took the drugs. Dyschromia was also more common: 45.6% versus 17.0%. Overall, 66.3% of GLP-1 users reported any nail disorder, compared with 52.8% of non-users.
The association persisted after adjusting for comorbidities and prior nail problems, with odds ratios of roughly 2–4 for onycholysis and dyschromia. However, in an analysis limited to new-onset nail lesions that appeared after starting GLP-1 treatment, the difference disappeared. The researchers said the true association likely lies between the fully adjusted and new-onset results, leaving open the possibility of a direct drug effect. Notably, about half of GLP-1 users had nail problems before starting treatment, and the data were self-reported via an online survey without dermatologic examination.
Outside experts urged caution. Joe Tung, MD, of the University of Pittsburgh Medical Center, said the findings should not worry patients doing well on GLP-1 medications, and that the most rigorous analysis showed no association. He noted that rapid weight loss and reduced protein intake could affect nails, similar to hair shedding. The investigators themselves said clinicians should ask patients about nail changes and consider a possible drug effect, but the results alone do not justify stopping an otherwise beneficial therapy.